Literature DB >> 25151947

Troponins in heart failure.

T Omland1, H Røsjø1, E Giannitsis2, S Agewall3.   

Abstract

The signs and symptoms of heart failure are frequently unspecific and correlate poorly with objective indices of cardiac function. Objective assessment of cardiac function by echocardiography or other imaging modalities also correlate poorly with symptomatic status and functional capacity. Accordingly, there is a need for circulating biomarkers that can provide incremental diagnostic and prognostic information to the existing armamentarium of tests. The introduction of more sensitive assays that allow determination of very low circulating concentrations of the myofibrillar proteins cardiac troponin I and T has not only resulted in improved diagnostic accuracy in the setting of acute coronary syndromes. The high sensitivity assays have also shown that cardiac troponins are frequently found chronically circulating in a variety of acute and chronic, cardiac and non-cardiac disease conditions, including acute heart failure and chronic symptomatic and asymptomatic left ventricular dysfunction. Cardiac troponin I and T provide may provide clinically useful prognostic information both concerning the future risk of developing heart failure in asymptomatic subjects and the risk of fatal events and hospital admissions in those with already established heart failure This review summarizes current literature on the clinical performance and utility of cardiac troponin measurements as diagnostic and prognostic tools in patients with symptomatic heart failure, as well as in those with asymptomatic left ventricular dysfunction, and clinical phenotypes at high risk for developing heart failure, including stable coronary artery disease, left ventricular hypertrophy, and aortic stenosis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk marker; Heart failure; Troponin

Mesh:

Substances:

Year:  2014        PMID: 25151947     DOI: 10.1016/j.cca.2014.08.016

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death.

Authors:  John W McEvoy; Yuan Chen; Chiadi E Ndumele; Scott D Solomon; Vijay Nambi; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

Review 2.  High-sensitivity assays for troponin in patients with cardiac disease.

Authors:  Dirk Westermann; Johannes Tobias Neumann; Nils Arne Sörensen; Stefan Blankenberg
Journal:  Nat Rev Cardiol       Date:  2017-04-06       Impact factor: 32.419

3.  High-sensitivity cardiac troponin T and severity of cerebral white matter lesions in patients with acute ischemic stroke.

Authors:  Regina von Rennenberg; Bob Siegerink; Ramanan Ganeshan; Kersten Villringer; Wolfram Doehner; Heinrich J Audebert; Matthias Endres; Christian H Nolte; Jan F Scheitz
Journal:  J Neurol       Date:  2018-10-11       Impact factor: 4.849

4.  S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.

Authors:  Ufuk Eryilmaz; Buket Demirci; Saliha Aksun; Murat Boyacioglu; Cagdas Akgullu; Tevfik Fikret Ilgenli; Hande Sultan Yalinkilinc; Mehmet Bilgen
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

5.  The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients.

Authors:  Anke Neukamm; Gunnar Einvik; Arne Didrik Høiseth; Vidar Søyseth; Nils Henrik Holmedahl; Natalia Kononova; Torbjørn Omland
Journal:  BMC Pulm Med       Date:  2016-11-25       Impact factor: 3.317

Review 6.  Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.

Authors:  Alexander E Berezin
Journal:  J Circ Biomark       Date:  2016-03-16

7.  Association Between High-Sensitivity Cardiac Troponin I and Cardiac Events in Elderly Women.

Authors:  Joshua R Lewis; Wai H Lim; Germaine Wong; Samuel Abbs; Kun Zhu; Ee M Lim; Peter L Thompson; Richard L Prince
Journal:  J Am Heart Assoc       Date:  2017-07-30       Impact factor: 5.501

Review 8.  Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player.

Authors:  Marian Wesseling; Julius H C de Poel; Saskia C A de Jager
Journal:  ESC Heart Fail       Date:  2020-05-18

Review 9.  Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs.

Authors:  Apurva Shrivastava; Tina Haase; Tanja Zeller; Christian Schulte
Journal:  Front Cardiovasc Med       Date:  2020-11-23

10.  Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.

Authors:  Faiez Zannad; Barry Greenberg; John G F Cleland; Mihai Gheorghiade; Dirk J van Veldhuisen; Mandeep R Mehra; Stefan D Anker; William M Byra; Min Fu; Roger M Mills
Journal:  Eur J Heart Fail       Date:  2015-04-27       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.